Thalia Vlachou

Thalia Vlachou

Auto-generated profile, based on publicly available information

Thalia Vlachou

Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2016 in EMBO Reports
Verified
Journal Article
Closed access
PDF file
ASAngela Santoro
Angela Santoro
TVThalia Vlachou
Thalia Vlachou
MCManuel Carminati
Manuel Carminati
Pier Giuseppe PelicciPier Giuseppe Pelicci
Pier Giuseppe Pelicci
MMMarina Mapelli
Marina Mapelli

1 January 2019 in Cell Reports
Verified
Journal Article
Open access
ASAngela Santoro
Angela Santoro
TVThalia Vlachou
Thalia Vlachou
LLLucilla Luzi
Lucilla Luzi
GMGiorgio Melloni
Giorgio Melloni
Luca MazzarellaLuca Mazzarella
Luca Mazzarella
Pier Giuseppe PelicciPier Giuseppe Pelicci
Pier Giuseppe Pelicci
Loss of p53 function is invariably associated with cancer. Its role in tumor growth was recently linked to its effects on cancer stem cells (CSCs), although the underlying molecular mechanisms remain unknown. Here, we show that c-myc is a transcriptional target of p53 in mammary stem cells (MaSCs) and is activated in breast tumors as a consequence of p53 loss. Constitutive Myc expression in normal mammary cells leads to increased frequency of MaSC symmetric divisions, extended MaSC replicative-potential, and MaSC-reprogramming of progenitors, whereas Myc activation in breast cancer is necessary and sufficient to maintain the expanding pool of CSCs. Concomitant p53 loss and Myc activation trigger the expression of 189 mitotic genes, which identify patients at high risk of mortality and relapse, independently of other risk factors. Altogether, deregulation of the p53:Myc axis in mammary tumors increases CSC content and plasticity and is a critical determinant of tumor growth and clinical aggressiveness.

17 June 2025 in EMBO Reports
Verified
Journal Article
Open access
FLFiorenza Lotti
Fiorenza Lotti
MMMarine Melixetian
Marine Melixetian
TVThalia Vlachou
Thalia Vlachou
Marco S. NobileMarco S. Nobile
Marco S. Nobile
LBLeone Bacciu
Leone Bacciu
LLLuisa Lanfrancone
Luisa Lanfrancone
Melanoma exhibits high intratumoral heterogeneity, characterized by a diverse population of cells undergoing dynamic transitions between cellular states. These adaptive changes enable melanoma cells to survive in the harsh tumor microenvironment, acquire drug resistance, and metastasize. One such state, quiescence, has been linked to both relapse and drug resistance, but its underlying biology and molecular mechanisms remain poorly understood. Our study challenges the conventional understanding of melanoma quiescence. Contrary to the notion of a rare, unique subpopulation, we demonstrate that quiescence is a highly dynamic state accessible to most, if not all, melanoma cells. This state is exquisitely sensitive to microenvironmental cues. We identify GPNMB as a marker of quiescence, that is expressed in both primary and metastatic tumors. GPNMB-positive cells exhibit a pro-metastatic phenotype and are enriched in metastatic sites, suggesting a potential role for quiescence in tumor dissemination. Our findings position GPNMB as a valuable marker for isolating quiescent melanoma cells and as a potential therapeutic target to tackle metastasis.

2 August 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
LFLotti Fiorenza
Lotti Fiorenza
MMMeliksetyan Marine
Meliksetyan Marine
MMMarco Malferrari
Marco Malferrari
QNQuaresima Nicolò
Quaresima Nicolò
SRStefania Rapino
Stefania Rapino
LLLuisa Lanfrancone
Luisa Lanfrancone
Melanoma is a heterogeneous tumor composed of many interacting cellular populations and highly plastic melanoma cells that pass through distinct cell states to adapt to the surrounding microenvironment. Slow cycling is a transient state that defines a minor population of cells with cancer-initiating features. These cells are enriched upon drug therapy and can trigger cancer relapse and metastasis dissemination when they acquire proliferative potential. This population is still not entirely characterized. Here we provide evidence of the existence of a slow cycling melanoma population isolated in vivo from melanoma PDXs using the H2B-GFP system. These cells display a highly invasive phenotype and are able to dynamically respond to cancer microenvironmental stimuli. Single cell transcriptomic analysis unveils a significant transcriptional heterogeneity of GFP-retaining slow cycling cells, defining a quiescent subpopulation of cells. These cells show a different phenotype in primary tumors and matched metastases, suggesting that tumor niche pressure drives a transcriptional reprogramming of quiescent cells during melanoma progression.

26 September 2017
Verified
Book Chapter
Closed access
PDF file
TVThalia Vlachou
Thalia Vlachou
GCGiulia De Conti
Giulia De Conti
ASAnna Giulia Sanarico
Anna Giulia Sanarico
Pier Giuseppe PelicciPier Giuseppe Pelicci
Pier Giuseppe Pelicci